Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Thymoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Colonic Neoplasms 1

Interventions

Ifosfamide 6Leucovorin 5Doxorubicin 4Dexrazoxane 4Cisplatin 4Methotrexate 3Filgrastim 3Carboplatin 3mifamurtide 2glucarpidase 2Radiotherapy 2Neoadjuvant Therapy 2Mesna 2Granulocyte-Macrophage Colony-Stimulating Factor 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Cryosurgery 2Chemotherapy, Adjuvant 2temsirolimus 1sintilimab 1sargramostim 1saracatinib 1samarium Sm-153 lexidronam 1robatumumab 1pembrolizumab 1pegfilgrastim 1pazopanib 1omburtamab I-131 1niraparib 1lexatumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Osteosarcoma × saracatinib × Clear all
NCT00752206 2020-01-18

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

Sarcoma Alliance for Research through Collaboration

Phase 2 Terminated
38 enrolled 10 charts
Sarcoma

Recurrence, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡